The test is designed to identify and differentiate between Zika, dengue, and chikungunya in serum samples, even in the presence of more than one target.
In an SEC document, the company said net proceeds are expected to be $5.8 million and will be used to support an anticipated submission to the FDA, among other things.
The researchers said that affordable tests that can differentiate malaria from similar diseases is vital for administering the most targeted treatment for patients.
The company has been gearing up to submit its Acuitas AMR Gene Panel product to the US Food and Drug Administration for regulatory clearance.
The deals cover the Finnish diagnostic company's Amplidiag and Novodiag lines of infectious disease and antibiotic resistance testing products.
The firm missed the consensus Wall Street estimate on the bottom line, even as its ePlex analyzer Q4 revenues more than doubled year over year to $12.1 million.
The firm's technology can perform in-droplet centrifugation, 10-second cell lysis, and sound wave-based PCR on the surface of an inexpensive polymer chip.
The British molecular diagnostics firm recently completely a redesign of its point-of-care system, called Q-POC, and is planning to seek a CE-IVD mark for the device later this year.
Researchers profiled cervical microbe communities in relation to HPV, HIV, and cervical cytology status, identifying microbial shifts in high-grade lesions and HIV-positive cases.
The firms said that HuaSin obtained exclusive rights to develop a fully automated HPV genotyping assay platform that uses Genomica’s technology.
The companies have signed a licensing agreement related to bioinformatics tools to enable antimicrobial resistance research.
Researchers used genomic, transcriptomic, and virulence data on thousands of Streptococcus pyogenes strains to identify features influencing infections.
The Polish company recently received 9 million Polish złoty ($2.4 million) from the country's National Center for Research and Development to support its activities.
Many variants that became more prevalent in different rabbit populations after viral exposure were associated with immune system functions, a new study suggests.
OmniVis is developing the assay for cholera detection in environmental samples while the lab that created it is working toward a paper-based HIV test.
While the study showed initial promise, further work will be necessary to clarify its performance for various clinical indications.
The assay's CE marking permits its use for the early diagnosis of HIV-1 in infants and for measuring viral load and disease progression using dried blood spot samples.
Cardiac immunoassays paced revenue growth in Q4. The firm also saw an 88 percent jump in total revenues for 2018, supported by 43 percent growth in molecular diagnostics.
As part of the Human Vaccines Project, researchers sequenced samples from three adults and three infants to identify sets of shared and unique circulating B cell receptors.
The assay, which uses the Bioneer ExiStation molecular diagnostics instrument, was also recently registered for purchase by the Global Fund.
The Oregon state Senate unanimously passed a bill that would make it easier for people convicted of crimes to initiate DNA testing of evidence, according to the Associated Press.
People reports that researchers have uncovered genetic variants that lead people to always feel full.
Florida state senators are to weigh a bill prohibiting life insurance companies from using genetic information in coverage decisions, according to Florida Politics.
In Genome Research this week: metagenomic sequencing assay that detects pathogens in cerebrospinal fluid, single-tube long fragment read approach, and more.